Table 4.

Effect of replenishing Qi and activating blood on Aβ protein content in the cerebrospinal fluid in APP/PS1 double transgenic ischemic mice of each group (ng/mL, $\bar{x}±s$)

Group	Dose (mg·kg-1·d-1)	n	Aβ
C57 sham-operated	-	10	0.79±0.25
C57 ischemia	-	10	1.06±0.16
APP/PS1 model	-	10	1.22±0.27a
APP/PS1 ischemia	-	10	1.52±0.13b
C57BL ischaemic + aspirin	32	10	0.75±0.29
C57BL ischaemic + SLT	32	10	0.79±0.29
APP/PS1 + SLT	32	10	0.75±0.29
APP/PS1 ischaemic + donepezil hydrochloride	20	10	0.82±0.30c
APP/PS1 ischaemic + SLT	32	10	0.79±0.26c

Notes: ischaemic treatment: both right and left common carotid arteries were separated, and the arterial blood vessel was stimulated with a temperature-controlled current of 80 mu A using an in vivo thrombometer to cause thrombosis. The APP/PS1 ischaemic + donepezil hydrochloride group were administered intragastrically with 20 mg·kg^-1·d^-1 of donepezil hydrochloride. The C57BL ischaemic + aspirin group were administered intragastrically with 32 mg·kg^-1·d^-1 of aspirin, the SLT group were administered intragastrically with 32 mg·kg^-1·d^-1 of SLT and the control group were given 32 mg·kg^-1·d^-1 of solvent. Duration: two months. SLT: Sailuotong; APP: amyloid precursor protein; PS1: presenilin-1. One-way analysis of variance was employed to make comparisons among groups, and in the case of the normal distribution, Tukey’s post hoc test was conducted; otherwise, the Kruskal-Wallis test was adopted. Compared with C57 sham-operated group, ^aP < 0.05, ^bP < 0.01; compared with APP/PS1 ischemia group, ^cP < 0.01.